ESG Advisory Market Size, Share, & Industry Analysis Report: By Type (Environmental Advisory, Social Responsibility Advisory), By Application, By Industry, By Size, and By Region – Market Forecast, 2025–2034

The ESG advisory market size is expected to reach USD 135.90 billion by 2034, according to a new study by Polaris Market Research. The report “ESG Advisory Market Share, Size, Trends, Industry Analysis Report: By Type (Environmental Advisory, Social Responsibility Advisory), By Application, By Industry, By Size, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

ESG advisory is a professional service that guides organizations in adopting sustainability, ethical governance, and social responsibility into their core decision-making processes. The integration of ESG metrics into long-term corporate strategy and value-creation models is boosting growth opportunities. Companies are adopting ESG as a strategic imperative to manage risks, improve brand reputation, and align with stakeholder values in sustainable finance as they move beyond basic compliance. Additionally, ESG advisors play a crucial role in helping businesses identify material issues, develop actionable roadmaps, and ensure that sustainability becomes a driver of competitive advantage throughout the organization.

The increasing demand for data-driven ESG solutions, driven by the need for transparent, measurable, and verifiable outcomes, further drives the expansion opportunities. Companies are under growing pressure to demonstrate real impact through credible metrics and standardized reporting frameworks. This has driven ESG advisory firms to enhance their analytical capabilities, leveraging digital transformation and performance benchmarks to deliver more in-depth insights. The focus on measurable ESG performance is expected to boost, reinforcing the role of advisory services in ensuring data integrity and strategic alignment as expectations from investors, regulators, and consumers evolve.

ESG advisory Market Report Highlights

In terms of application, the strategy development and integration services segment accounted for the largest market share, reflecting organizations' growing focus on embedding ESG principles into their fundamental business models and operational frameworks.

Based on type, the ESG reporting and disclosure segment is anticipated to experience the most rapid expansion in the coming years, due to the swift advancement of global regulatory standards and heightened investor demand for corporate transparency.

North America led the ESG advisory market in revenue share during 2024, attributed to its well-established regulatory infrastructure, active investor engagement, and robust institutional emphasis on ESG adherence.

Asia Pacific is expected to register substantial growth over the forecast period, driven by increasing environmental consciousness, dynamic regulatory developments, and expanding international investor interest in regional sustainability initiatives.

A few global key market players include Bain & Company, Inc.; Boston Consulting Group; Deloitte Touche Tohmatsu Limited; Ernst & Young Global Limited; McKinsey & Company; MSCI Inc.; Nexio Projects; PwC; Sustainalytics; and The ERM International Group Limited.

Polaris Market Research has segmented the market report on the basis of type, application, industry, size, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

Environmental Advisory

Social Responsibility Advisory

Governance & Ethics Advisory

ESG Reporting & Disclosure

By Application Outlook (Revenue, USD Billion, 2020–2034)

Strategy Development & Integration

Compliance & Risk Management

Reporting & Transparency

Stakeholder Engagement

By Industry Outlook (Revenue, USD Billion, 2020–2034)

Energy & Utilities

Manufacturing

Financial Services

Technology

Healthcare

By Size Outlook (Revenue, USD Billion, 2020–2034)

Large Enterprises

Medium Businesses

Small Businesses

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Source
3.2.1. Primary Source
3.2.2. Secondary Source
4. Global Epilepsy Drugs Market Insights
4.1. Epilepsy Drugs Market – Market Snapshot
4.2. Epilepsy Drugs Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing Prevalence of Epilepsy
4.2.1.2. Advancements in Antiepileptic Drug Development
4.2.2. Restraints and Challenges
4.2.2.1. Drug resistance in a significant percentage of epilepsy patients
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Epilepsy Drugs Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Epilepsy Drugs Market, by Type
5.1. Key Findings
5.2. Introduction
5.2.1. Global Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
5.3. First Generation Anti-epileptics
5.3.1. Global Epilepsy Drugs Market, by First Generation Anti-epileptics, by Region, 2020–2034 (USD Billion)
5.4. Second Generation Anti-epileptics
5.4.1. Global Epilepsy Drugs Market, by Second Generation Anti-epileptics, by Region, 2020–2034 (USD Billion)
5.5. Third Generation Anti-epileptics
5.5.1. Global Epilepsy Drugs Market, by Third Generation Anti-epileptics, by Region, 2020–2034 (USD Billion)
6. Global Epilepsy Drugs Market, by Route of Administration
6.1. Key Findings
6.2. Introduction
6.2.1. Global Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
6.3. Oral
6.3.1. Global Epilepsy Drugs Market, by Oral, by Region, 2020–2034 (USD Billion)
6.4. Intravenous
6.4.1. Global Epilepsy Drugs Market, by Intravenous, by Region, 2020–2034 (USD Billion)
6.5. Intra-muscular
6.5.1. Global Epilepsy Drugs Market, by Intra-muscular, by Region, 2020–2034 (USD Billion)
7. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type
7.1. Key Findings
7.2. Introduction
7.2.1. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
7.3. Narrow-Spectrum AEDs
7.3.1. Global Epilepsy Drugs Market, by Narrow-Spectrum AEDs, by Region, 2020–2034 (USD Billion)
7.4. Broad-Spectrum AEDs
7.4.1. Global Epilepsy Drugs Market, by Broad-Spectrum AEDs, by Region, 2020–2034 (USD Billion)
8. Global Epilepsy Drugs Market, by Geography
8.1. Key Findings
8.2. Introduction
8.2.1. Epilepsy Drugs Market Assessment, By Geography, 2020–2034 (USD Billion)
8.3. Epilepsy Drugs Market – North America
8.3.1. North America: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.3.2. North America: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.3.3. North America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.3.4. Epilepsy Drugs Market – U.S.
8.3.4.1. U.S.: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.3.4.2. U.S.: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.3.4.3. U.S.: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.3.5. Epilepsy Drugs Market – Canada
8.3.5.1. Canada: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.3.5.2. Canada: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.3.5.3. Canada: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4. Epilepsy Drugs Market – Europe
8.4.1. Europe: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.2. Europe: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.3. Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.4. Epilepsy Drugs Market – UK
8.4.4.1. UK: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.4.2. UK: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.4.3. UK: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.5. Epilepsy Drugs Market – France
8.4.5.1. France: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.5.2. France: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.5.3. France: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.6. Epilepsy Drugs Market – Germany
8.4.6.1. Germany: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.6.2. Germany: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.6.3. Germany: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.7. Epilepsy Drugs Market – Italy
8.4.7.1. Italy: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.7.2. Italy: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.7.3. Italy: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.8. Epilepsy Drugs Market – Spain
8.4.8.1. Spain: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.8.2. Spain: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.8.3. Spain: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.9. Epilepsy Drugs Market – Netherlands
8.4.9.1. Netherlands: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.9.2. Netherlands: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.9.3. Netherlands: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.10. Epilepsy Drugs Market – Russia
8.4.10.1. Russia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.10.2. Russia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.10.3. Russia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.4.11. Epilepsy Drugs Market – Rest of Europe
8.4.11.1. Rest of Europe: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.4.11.2. Rest of Europe: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.4.11.3. Rest of Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5. Epilepsy Drugs Market – Asia Pacific
8.5.1. Asia Pacific: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.2. Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.3. Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.4. Epilepsy Drugs Market – China
8.5.4.1. China: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.4.2. China: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.4.3. China: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.5. Epilepsy Drugs Market – India
8.5.5.1. India: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.5.2. India: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.5.3. India: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.6. Epilepsy Drugs Market – Malaysia
8.5.6.1. Malaysia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.6.2. Malaysia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.6.3. Malaysia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.7. Epilepsy Drugs Market – Japan
8.5.7.1. Japan: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.7.2. Japan: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.7.3. Japan: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.8. Epilepsy Drugs Market – Indonesia
8.5.8.1. Indonesia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.8.2. Indonesia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.8.3. Indonesia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.9. Epilepsy Drugs Market – South Korea
8.5.9.1. South Korea: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.9.2. South Korea: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.9.3. South Korea: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.10. Epilepsy Drugs Market – Australia
8.5.10.1. Australia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.10.2. Australia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.10.3. Australia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.5.11. Epilepsy Drugs Market – Rest of Asia Pacific
8.5.11.1. Rest of Asia Pacific: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.5.11.2. Rest of Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.5.11.3. Rest of Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.6. Epilepsy Drugs Market – Middle East & Africa
8.6.1. Middle East & Africa: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.6.2. Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.6.3. Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.6.4. Epilepsy Drugs Market – Saudi Arabia
8.6.4.1. Saudi Arabia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.6.4.2. Saudi Arabia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.6.4.3. Saudi Arabia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.6.5. Epilepsy Drugs Market – UAE
8.6.5.1. UAE: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.6.5.2. UAE: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.6.5.3. UAE: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.6.6. Epilepsy Drugs Market – Israel
8.6.6.1. Israel: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.6.6.2. Israel: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.6.6.3. Israel: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.6.7. Epilepsy Drugs Market – South Africa
8.6.7.1. South Africa: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.6.7.2. South Africa: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.6.7.3. South Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.6.8. Epilepsy Drugs Market – Rest of Middle East & Africa
8.6.8.1. Rest of Middle East & Africa: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.6.8.2. Rest of Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.6.8.3. Rest of Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.7. Epilepsy Drugs Market – Latin America
8.7.1. Latin America: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.7.2. Latin America: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.7.3. Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.7.4. Epilepsy Drugs Market – Mexico
8.7.4.1. Mexico: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.7.4.2. Mexico: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.7.4.3. Mexico: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.7.5. Epilepsy Drugs Market – Brazil
8.7.5.1. Brazil: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.7.5.2. Brazil: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.7.5.3. Brazil: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.7.6. Epilepsy Drugs Market – Argentina
8.7.6.1. Argentina: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.7.6.2. Argentina: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.7.6.3. Argentina: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
8.7.7. Epilepsy Drugs Market – Rest of Latin America
8.7.7.1. Rest of Latin America: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
8.7.7.2. Rest of Latin America: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
8.7.7.3. Rest of Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Abbott Laboratories
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Eisai Co., Ltd.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. GlaxoSmithKline plc
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Jazz Pharmaceuticals plc
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Neurelis Inc.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Novartis AG
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Pfizer Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Sanofi
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Sun Pharmaceutical Industries Limited
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Pharma)
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Takeda Pharmaceutical Company
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. UCB S.A.
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings